L-163,491: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:L-163491 structure.png|L-163,491 | |||
</gallery> | |||
Revision as of 01:42, 20 February 2025
L-163,491 is a drug that acts as a potent and selective antagonist for the receptor AT1 subtype. It has been used in the research of hypertension and other cardiovascular conditions.
Pharmacology
L-163,491 is a non-peptide Angiotensin II receptor antagonist that selectively inhibits the AT1 subtype. This receptor subtype is primarily responsible for the vasoconstrictive effects of angiotensin II, a hormone that plays a crucial role in regulating blood pressure and fluid balance.
Medical Uses
L-163,491 has been used in scientific research to study the role of the AT1 receptor in various cardiovascular conditions, including hypertension, heart failure, and myocardial infarction. By blocking the action of angiotensin II at the AT1 receptor, L-163,491 can help to lower blood pressure and reduce the risk of these conditions.
Side Effects
As with all drugs, L-163,491 can potentially cause side effects. However, as it is primarily used in research rather than in clinical practice, the full range of its side effects is not well known.
See Also
References
<references />
